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Abstract
Background: Improving maternal health has been a primary goal of international health agencies for many years,
with the aim of reducing maternal and child deaths and improving access to antenatal care (ANC) services,
particularly in low-and-middle-income countries (LMICs). Health interventions with these aims have received more
attention from a clinical effectiveness perspective than for cost impact and economic efficiency.
Methods: We collected data on resource use and costs as part of a large, multi-country study assessing the use of
routine antenatal screening ultrasound (US) with the aim of considering the implications for economic efficiency.
We assessed typical antenatal outpatient and hospital-based (facility) care for pregnant women, in general, with
selective complication-related data collection in women participating in a large maternal health registry and clinical
trial in five LMICs. We estimated average costs from a facility/health system perspective for outpatient and inpatient
services. We converted all country-level currency cost estimates to 2015 United States dollars (USD). We compared
average costs across countries for ANC visits, deliveries, higher-risk pregnancies, and complications, and conducted
sensitivity analyses.
Results: Our study included sites in five countries representing different regions. Overall, the relative cost of
individual ANC and delivery-related healthcare use was consistent among countries, generally corresponding to
country-specific income levels. ANC outpatient visit cost estimates per patient among countries ranged from 15 to
30 USD, based on average counts for visits with and without US. Estimates for antenatal screening US visits were
more costly than non-US visits. Costs associated with higher-risk pregnancies were influenced by rates of hospital
delivery by cesarean section (mean per person delivery cost estimate range: 25–65 USD).
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Conclusions: Despite substantial differences among countries in infrastructures and health system capacity, there
were similarities in resource allocation, delivery location, and country-level challenges. Overall, there was no clear
suggestion that adding antenatal screening US would result in either major cost savings or major cost increases.
However, antenatal screening US would have higher training and maintenance costs. Given the lack of clinical
effectiveness evidence and greater resource constraints of LMICs, it is unlikely that introducing antenatal screening
US would be economically efficient in these settings--on the demand side (i.e., patients) or supply side (i.e.,
healthcare providers).
Trial registration: Trial number: NCT01990625 (First posted: November 21, 2013 on https://clinicaltrials.gov).
Keywords: Maternal health, Antenatal care, Delivery, Cost, Health economics, Low-and-middle-income countries
Background
According to the World Health Organization, approxi-
mately 95% of maternal and 98% of neonatal deaths
occur in low- and middle-income countries (LMICs).
Global estimates from 2017 indicate that more than 800
women die each day due to preventable causes related to
pregnancy and childbirth [1]. Despite improvements in
maternal and child mortality in LMICs during the past
decades resulting from strategic investments and initia-
tives by countries, health organizations, and donors,
there is limited evidence consistently demonstrating the
clinical effectiveness of many interventions [2]. Assess-
ments of the economic impact of implementing innova-
tive strategies to improve health outcomes in LMICs
have received increased attention, but data gaps and
other challenges persist [3, 4].
Diagnostic tests present a compelling case for studying
the potential costs and consequences in LMICs of tech-
nologies used regularly in higher-income countries. One
challenge, however, of assessing the value of multi-use
diagnostic tests is that the same technology may have
several indications with differing value profiles associ-
ated with each type of use. Ultrasound (US), for ex-
ample, may be used to make hospital-based diagnoses,
and it also has been used as a screening tool for many
years during antenatal care (ANC) to identify high-risk
pregnancies, the presence of potential complications,
and to determine gestational age [5–7]. In LMICs, the
use of antenatal screening US was thought to potentially
add value by encouraging earlier ANC attendance, allow-
ing for earlier identification of high-risk pregnancies,
and helping mothers appropriately plan their ANC and
delivery based on their risk profile [8]. Our current
health economic study focuses only on the usage for
routine antenatal screening ultrasound, not on all uses
of ultrasound.
Innovations in US technologies have reduced equip-
ment size, improving portability and making point-of-
care US more feasible, resulting also in lower US
equipment acquisition costs over time. However, ques-
tions remain related to the appropriate, effective, and
efficient use of US for specific indications. Prior to mak-
ing large-scale investments in the adoption and diffusion
of portable US by global stakeholders, decision makers
can benefit from having more clinical and economic evi-
dence. The First Look cluster-randomized controlled
trial (CRCT) in five diverse LMICs generated evidence
about the clinical effectiveness of portable, community-
based, antenatal screening US by evaluating the impact
on maternal mortality, maternal near-miss, stillbirth, and
neonatal mortality [9, 10]. Given the “intermediate out-
comes” characteristic of screening or diagnostic tests, in-
cluding for ultrasound, it was important that our CRCT
and accompanying economic study also tracked non-
ultrasound antenatal care visits, patient referrals, deliver-
ies, and hospital-related events [11].
The current paper reports resource use and cost data
collected alongside this CRCT as part of assessing po-
tential economic efficiency gains of introducing ante-
natal screening US in five LMICs: Democratic Republic
of Congo (DRC), Guatemala, Kenya, Pakistan, and
Zambia. Our primary objective was to estimate average
patient-level costs for facilities in the participating coun-
tries for portable antenatal screening US use, general
ANC, and delivery events based on health facility loca-
tion and type of delivery. The overall trial results have
been reported and suggested that, in general, the intro-
duction of routine antenatal screening US is unlikely to
be more efficacious compared to standard of care [12].
Our cost estimation focused on aggregated estimates for
ANC-related use, delivery-related use, and complications
for combined standard of care and experimental inter-
vention groups in each country, due to the similar effect-
iveness and process outcomes found between arms in
the CRCT, implying similar event costs between groups.
Despite our original goal to assess costs in relation to ef-
fectiveness difference between groups, we believe these
data are still useful for others doing research related to
ANC or maternal health use and costs, or developing
policies on antenatal interventions in LMIC settings. We
describe the methods for generating our estimates,
present cost estimates for the five countries, and discuss
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potential implications for our findings for research prac-
tice and policy.
Methods
Overview and aims
The primary objective of this economic study performed
alongside the First Look CRCT was to estimate average
patient-level costs in participating countries comparing
the US group to standard of care. We collected resource
use for ANC visits and delivery-related events based on
health facility location and type of delivery (cesarean sec-
tion or vaginal birth). In addition, we wanted to estimate
facility-based costs associated with complications experi-
enced during pregnancy, at the time of delivery, and
during a six-week post-partum period. Our approach
was to establish unit costs for particular resource use,
and to construct key event average costs from these unit
cost estimates. We developed these cost estimates
through site visits in collaboration with local health re-
searchers, thus providing a clinic or hospital facility per-
spective for our use and cost assessment. We examined
relative prices within countries for different resources
and events, and converted them to 2015 United States
dollars (USD) for general comparisons across countries,
despite differences in health systems in participating
countries.
Population
Our study population included pregnant women en-
rolled in the CRTC intervention clusters and women in
control (standard of care) clusters participating in the
Global Network Maternal Newborn Health Registry (GN
MNHR) in five countries: the Democratic Republic of
Congo (DRC), Guatemala, Kenya, Pakistan, and Zambia
[13]. Each cluster was a defined geographic area gener-
ally served by a single health center and its catchment
area with roughly 500 births per year. Further details
about the CRCT study population and study design are
detailed elsewhere [12]. The CRCT adhered to CON-
SORT guidelines and the CONSORT diagram is pre-
sented in Supplemental Figure 1. The overall sample
included normal (low-risk) pregnancies and high-risk
pregnancies identified as multiple gestation, placenta
previa, and breech presentation. Each participant pro-
vided written informed consent prior to study participa-
tion, including for the use of their study data.
Data sources
We used three primary data sources to inform our eco-
nomic assessment. First, for intervention clusters, we
used the CRCT data on the number of ANC visits, deliv-
ery location, type of delivery (vaginal or cesarean
section), and select pregnancy-related complications col-
lected during a portion of the trial. Second, similar data
for the control-group clusters were obtained from the
GN MNHR [13]. Third, we collected average time and
cost estimates for typical ANC, delivery, and
complication-related interventions or events using con-
sistent, standard data collection tools in each country,
with local health experts interviewing hospital adminis-
trators and using reimbursement schedules as proxies
for costs when available. Due to similar outcomes ob-
served in the CRCT [12], we report country-level aver-
ages for ANC and delivery-related resource use for all
intervention and control patients combined within each
country for the average probability parameters of visit-
related or facility-related events.
Our cost estimates focused on public health facilities
in participating countries, at the local health clinic level
and the hospital (facility) level. We also included private
facility data collection in Pakistan, DRC, and Kenya to
provide a range of estimates. Data collection in Zambia
included several public facilities, most often with similar
fee structures. We obtained data from one representative
rural public hospital in Guatemala.
Perspective of cost assessment
The perspective for the cost assessment was a health fa-
cility perspective and this can be viewed as a health
delivery-system perspective, accounting for visits, deliv-
eries, and complication events. We focused on facility-
related reimbursement for services, despite the fact that
some countries do not have public or private health in-
surance provision for our study participants for ANC or
delivery services, implying mothers or families incur the
financial burden rather than via payer reimbursement.
Time horizon of resource use
The period of our data collection included visits or com-
plications during the ANC pre-delivery period, the deliv-
ery event, and a 6-week period post-delivery during
which complications were managed in a hospital setting.
Types of average cost data collected
We collected data on average gross-level costs for typical
ANC resource use and delivery-related events, as well as
low and high ranges for each type of service. We used
per patient average cost estimates to calculate ANC and
in-hospital costs for patient care. Our data tools in-
cluded the collection of inpatient and outpatient ANC
costs, as well as costs for delivery-related events and
pregnancy-related complication event care. For the cost
estimation, we did not have data for specific CRCT pa-
tient events in the hospital or assess patient-related
clinic or hospital records such as for hospital stays re-
lated to pregnancy complications or delivery events. All
costs were reported in local currencies and converted to
2015 USD for comparisons [14]. We converted average
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cost estimates to 2015 USD with exchange rates listed in
Table 1 [15–19]. We did not calculate costs for US
equipment, training sonographers, or maintaining equip-
ment/training.
Estimating antenatal care resource use, other resource
use, and costs in countries
We calculated the average amount of resources used as-
sociated with ANC visits (with and without antenatal
screening US), procedures, or interventions including
outpatient and inpatient services, hospital stays and in-
facility delivery procedures, and resource use based on
reported complications in a portion of study participants
(trial and registry). Cost and probability estimates for
standard ANC services and complication-related services
performed in facility settings for maternal and neonatal
complications were used to estimate resource use and
event costs. Although antenatal screening US use was
primarily based on use in one randomized cohort in the
CRCT (i.e., intervention group), we provide an overall
estimate of ANC costs based on the average number of
antenatal screening US visits recorded for patients in the
trial. We calculated a combined ANC visit cost estimate
that included non-US visits and antenatal screening US
visits recorded for each country-level sample from the
CRCT, subtracting the estimated number of US visits
from the overall number of ANC visits to avoid double
counting.
For ANC visits, the average number of visits reported
in countries was multiplied by the outpatient facility cost
of an ANC visit, for visits without US and for visits in-
cluding antenatal screening US. The average number of
ANC visits calculation used data from the GN MNHR
and the CRCT. The average number of overall ANC
visits in countries was calculated net of the proportion
of patients with one, two, three, or four or more US
visits using reported visits from the CRCT. A small per-
centage of persons (all countries < 1%) with more than
four visits with antenatal screening US were assumed to
have four US visits for ANC cost calculations.
Our facility-level “gross costing” reimbursement-based
approach used reported average cost data for each type
of visit or other service provided in a health facility, or
outpatient setting for ANC visits. Although country-
level data collection included estimates from several fa-
cilities, available services differed at specific facilities
within countries, resulting in some zero dollar cost esti-
mates for services when they were not available in a par-
ticular facility. For country-level average cost estimates,
only cost estimates greater than zero were used for base-
case estimates when a resource item was available at fa-
cilities in countries. Some services in countries were
bundled as part of overall delivery-related episode-based
reimbursement and thus did not have item-level cost
estimates.
Probabilities for delivery location were obtained from
the CRCT and GN MNHR data, indicating whether de-
liveries occurred at one of three settings: local/village,
non-hospital clinic, or a hospital/health center. Average
costs for deliveries based on delivery location were esti-
mated using the unit cost estimate for services and the
proportion of mothers reported to have delivered using
cesarean section. We used CRCT and GN MNHR data
for cesarean delivery rates and assumed cesarean deliver-
ies occurred only in the hospital facility for costing pur-
poses. For these deliveries we also used country-level
unit costs for hospital stays associated with cesarean
deliveries. We did not assume hospital stay costs for
non-cesarean deliveries. Delivery costs for a subset of
mothers identified with higher-risk pregnancies are also
reported. Countries with public reimbursement mecha-
nisms, e.g., Kenya and Zambia, reported “lump sum” es-
timates for deliveries in public facilities which included
payment (cost) for services associated with addressing
birth-related complications in mothers and children.
Since we did not have a facility unit cost estimate for
local-level or clinic-level deliveries, base case estimates
assumed a proportion of the hospital-based delivery cost
for a non-cesarean delivery, at a 25% rate for local/vil-
lage deliveries, and 50% for non-hospital clinic deliveries.
Table 1 Select population-level statistics for countries participating in the trial (2015)
2015 rates/statistics DRC Kenya Zambia Guatemalac Pakistan
Population (1000’s) 77,267 46,050 16,212 14,389 188,925
Per capita income (USD 2015) 497b 1337b 1332b 3924b 1357b
Currency exchange rate per 1 USD (June 2015 USD) 921.29 99.19 7.55 7.63 101.82
Total live births (1000’s) 3217 1571 645 467 5451
Maternal mortality ratioa (per 100 live births) 0.6930 0.5100 0.2240 0.1100 0.1780
Neonatal mortality rateb (per 100 live births) 3 2.2 2.1 1.5 4.6
Calculated ratio of neonatal mortality to maternal mortality (per 100 live births) 4.33 4.31 9.38 13.64 25.84
Notes: aConverted to per 100 live births from per 100,000,
bConverted to per 100 live births from per 1000
cLatest available mortality statistics for Guatemala were from 2010
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Base-case estimates used reported unit cost averages and
a range for cesarean delivery costs for the hospital
services.
The use of select hospital/referral services for treat-
ment of complications was reported in a sub-sample of
the CRCT for maternal complications in the GN MNHR
for neonatal complications, along with major services
used. Since we expected hospital-based management for
complications to be a higher-cost item, we incorporated
pregnancy-related complication collection at sites, to
complement similar GN MNHR data on complications.
We used these reported proportions of maternal and
neonatal complications and applied unit cost estimates
to each type of service to estimate average facility-based
management costs for these types of typical complica-
tions. Maternal health complication management in-
cluded treatment with antibiotics, hysterectomy or other
surgery, use of anesthesia or blood transfusion, and
whether inpatient US or chest radiograph was used. Se-
lect neonatal services use included hospitalizations, neo-
natal bath, antibiotics, oxygen, mechanical ventilator,
medical eye or cord care, and vitamin K treatment. Unit
prices for services were multiplied times the proportion
of patients in the CRCT or GN MNHR reporting use of
these services specifically for pregnancy-related compli-
cations. Countries with public reimbursement mecha-
nisms, e.g., Kenya and Zambia, reported “lump sum”
estimates for deliveries in public facilities which repre-
sented full reimbursement (cost) for services associated
with managing complications in mothers and children.
Thus select resource use items in countries are indicated
as zero USD cost estimates. In some cases zero USD
unit costs indicate the lowest-resourced rural hospitals
sampled did not have all services/equipment available,
such as in DRC.
Sensitivity testing of specific parameters
Sensitivity analysis was conducted for select ANC visit
costs and delivery costs for countries. ANC visits with
and without antenatal screening US were primary vari-
ables of interest and the low and high ranges of these
outpatient items were used in testing the impact on
ANC visit-related average costs, using the average num-
ber of each type of visit in our country-level cohorts. For
each country, we first used the low range cost estimates
of ANC visits with and without US as well as the high
ranges of each type of visit (two-way sensitivity). We
then used the low and high range of either ANC with or
without US and the base-case cost estimate of the other
type of visit (one-way sensitivity analysis). Likewise, low
and high ranges of delivery cost variables were tested in
sensitivity analysis, for both cesarean and non-cesarean
modes of delivery. In addition, since our data collection
focused on hospital facility-level cost estimation, we did
not have cost estimates for home- or village-level deliv-
eries or clinic-level deliveries. Therefore, we adjusted
our proportional cost assumptions for home/village de-
liveries and clinic-level deliveries from 25 and 50% (base
case) of hospital-based non-cesarean deliveries, respect-
ively, and tested 10 and 35% of hospital costs for home
−/village-level and 25 and 60% for clinic-level. To pro-
vide a high-end cost range for cesarean section deliveries
with complications, sensitivity analyses were performed
by incorporating additional hospital stay cost estimates
associated with 100% of cesarean deliveries, in addition
to the standard average costs for cesarean section
deliveries.
Results
Table 1 presents several population-level demographic
statistics for participating countries to provide context
for understanding variability in estimates among our
sample. Per capita Gross Domestic Product (GDP), a
measure of national income, varied substantially among
participating countries in 2015 (497 USD in DRC, 1337
USD in Kenya, 1332 USD in Zambia, and 3924 USD in
Guatemala, 1357 USD in Pakistan [14]. Population size
and live births per 1000 in the population also varied by
several fold, as well as maternal and neonatal mortality
rates per 100 live births.
Average cost estimates for outpatient clinic and facility-
based antenatal care and delivery care
Average per mother antenatal service use cost estimates
and ranges are presented in Table 2. Average item-level
costs of resources or services, i.e., reimbursement
amounts as proxies, generally varied in alignment with
income levels in countries, but not for all services. For
example, average cost estimates in countries for ANC
outpatient visits without antenatal screening US were
similar and ranged from 3─6 USD in countries. Out-
patient antenatal visits including antenatal screening US
were more variable in cost and estimated to be 4 USD in
Pakistan and Guatemala, while estimates ranged from
10─13 USD in DRC, Kenya, and Zambia. Low and high
ranges of estimates are also presented in Table 2 and
were used in sensitivity analyses. Select unit cost esti-
mates in the DRC, for example, such as for anesthesia
use, likely represent a high-end cost for services which
may not be available in rural health facilities or may not
be reimbursed at that level. Lower antenatal screening
US costs in Pakistan and Guatemala are likely related to
US being more available in their healthcare systems.
Additional estimates presented in Table 2 include cost
ranges for standard ANC resource use including hospital
stays, deliveries in hospital facilities with and without
cesarean section and estimates for managing complica-
tion events. Hospital overnight stays per night ranged
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Table 2 Facility-related unit cost estimates for antenatal care services in countries (2015 USD)
Dem. Rep. of Congo Kenya Zambia Guatemala Pakistan
Average Low High Average Low High Average Low High Average Low High Average Low High
Facility Costs
Outpatient
ANC Visit
4.70 0.54 16.28 4.41 1.01 10.08 5.74 3.97 9.27 3.28 2.88 3.67 3.72 1.47 6.87
Inpatient ANC
Visit
3.80 3.80 3.80 12.78 5.04 40.33 7.87 6.62 9.27 3.15 2.62 3.54 3.72 1.47 6.87
Outpatient
Ultrasound
Visit
12.83 2.00 30.00 10.33 8.07 15.12 13.25 6.62 19.87 4.19 3.41 4.98 4.30 2.46 5.89
Inpatient
Ultrasound
Visit
16.28 16.28 16.28 10.64 8.07 15.12 13.25 6.62 19.87 5.50 4.46 6.55 4.30 2.46 5.89
Consultation
with a
Specialist,
separate from
ultrasound
9.77 9.77 9.77 4.44 0.20 10.08 16.56 13.25 19.87 4.33 3.54 4.98 19.08 1.37 52.91
Hospital
Overnight Stay
2.97 1.58 5.43 4.11 1.01 9.07 23.18 19.87 26.49 17.04 15.07 19.13 14.35 4.91 23.41
ICU Overnight
Stay
12.10 1.58 30.39 0.00 0.00 0.00 46.36 39.74 52.98 69.72 46.13 93.32 141.27 98.21 176.78
Delivery in
hospital with
cesarean
section
108.50 10.85 287.64 156.27 50.41 272.20 99.34 79.47 119.21 44.46 39.15 49.80 202.85 116.87 294.64
Delivery in
hospital
without
cesarean
section
41.68 5.43 75.98 55.20 19.16 100.82 90.32 56.29 105.96 26.02 24.71 27.33 75.88 53.21 127.68
Neonatal
Resuscitation
with Bag and
Mask
N/A 0.00 0.00 N/A 0.00 0.00 3.31 1.59 6.62 1.57 1.31 1.83 4.66 4.39 4.92
Neonatal Bath N/A 0.00 0.00 N/A 0.00 0.00 1.32 0.66 1.99 1.31 1.18 1.31 N/A 0.00 0.00
Neonatal
Provision of
Antibiotics
7.00 5.00 30.00 7.06 5.04 9.07 1.32 0.66 1.99 8.26 8.13 8.26 6.53 3.38 14.73
Neonatal
Oxygen
29.31 29.31 29.31 1.01 1.01 1.01 1.32 0.66 1.99 6.16 5.11 7.21 4.66 4.39 4.92
Neonatal
Mechanical
Ventilation
N/A 0.00 0.00 N/A 0.00 0.00 1.32 0.66 1.99 39.58 32.77 46.40 4.66 4.39 4.92
Neonatal
Medicinal Eye
Care
0.71 0.54 0.87 0.20 0.20 0.20 1.32 0.66 1.99 4.72 4.33 5.11 N/A 0.00 0.00
Neonatal
Medicinal
Cord Care
N/A 0.00 0.00 N/A 0.00 0.00 1.21 0.13 1.99 0.66 0.52 0.79 N/A 0.00 0.00
Neonatal
Provision of
Vitamin K
1.90 0.54 3.26 2.02 2.02 2.02 0.74 0.13 1.99 1.31 1.31 1.44 0.58 0.58 0.58
Neonatal
Chest X-Ray
for Pneumonia
13.76 12.00 16.28 8.07 8.07 8.07 5.30 2.65 7.95 9.70 9.04 10.22 2.50 2.50 2.50
Neonatal
hospitalization
5.43 5.43 5.43 2.52 2.02 3.02 33.11 26.49 39.74 79.95 77.98 81.91 73.57 73.57 73.57
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from a low of 3 USD in the DRC to a high-end average
cost estimate of 23 USD in Zambia (Kenya 4 USD,
Guatemala 17 USD, and Pakistan 14 USD). Costs for
cesarean deliveries in all countries were higher than va-
ginal deliveries, with cesarean deliveries being roughly
twice as costly or more.
Table 3 presents probabilities for the location of
deliveries and maternal and neonatal events that were
captured and used to calculate costs deliveries and com-
plication events presented in Tables 4 and 5. Hospital
deliveries and cesarean deliveries were highest in
Guatemala, and lowest in DRC. Estimates in Table 4 ac-
count for scenarios with non-US visits and antenatal
screening US visits, deliveries based on recorded location
of child delivery (home/village, non-hospital clinic, and
hospital), and whether hospital deliveries used cesarean
section or non-cesarean methods.
Table 4 presents estimates of per person average
costs for ANC outpatient visits (without and with
US), as well as for a weighted average of combined
non-US visits and antenatal screening US visits,
roughly mimicking what would be expected in a typ-
ical patient cohort if antenatal screening US was used.
The average number of overall ANC visits (with or
without US) by country ranged from 3.20–4.45. If all
ANC visits were assumed to be without US, average
costs were estimated to be 15─18 USD in all coun-
tries. Total average costs for outpatient antenatal
screening US ranged from 7 USD to 24 USD in coun-
tries, based on a weighted average of the reported fre-
quency of US visits, primarily from the CRCT
intervention arm. The average number of visits with
antenatal screening US ranged from 1.53─1.97
among countries. Patients generally received one-three
scans and a small portion received four or more ante-
natal screening US scans. For a combined expected
total ANC cost for visits (non-US and antenatal
screening US visits), estimates ranged from 15─16
USD in Pakistan and Guatemala to 25─31 USD in
Kenya, DRC, and Zambia. In general, antenatal
screening US visits increased the overall estimate for
ANC visit costs, as a function of the unit cost esti-
mate for the antenatal screening US visits within
countries and the frequency of US visits. For example,
antenatal screening US visits in DRC were estimated
to cost more than double non-US ANC visits, while
in Guatemala and Pakistan, antenatal screening US
visit costs were estimated to be closer to ANC visits
without US.
Table 4 also presents estimates of delivery costs based
on the frequency of alternative birthing locations/set-
tings (local, clinic, and hospital). Per mother average de-
livery costs ranged from 23 USD in DRC and Guatemala
to 58 USD in Pakistan (31 USD in Kenya and 52 USD in
Zambia) for the overall sample available from the CRCT
and GN MNHR patients, based on reported delivery lo-
cation and type of delivery. Costs associated with
cesarean section deliveries were included based on the
percentage of these deliveries reported. Delivery cost es-
timates for high-risk pregnancies delivering in the three
settings are presented separately in Table 4. These sub-
sample pregnancies resulted in higher costs in all coun-
tries (roughly 10–28% greater per country) due to higher
cesarean section rates in the higher-risk group compared
Table 2 Facility-related unit cost estimates for antenatal care services in countries (2015 USD) (Continued)
Dem. Rep. of Congo Kenya Zambia Guatemala Pakistan
Average Low High Average Low High Average Low High Average Low High Average Low High
Hospital Stay
for C-Section
27.14 10.85 54.27 38.81 5.04 90.73 33.11 26.49 39.74 155.96 77.98 233.94 207.23 116.87 294.64
Treatment
with
Antibiotics
7.00 5.00 30.00 36.97 10.08 70.57 3.31 1.99 4.64 12.00 8.00 16.00 9.58 5.89 14.73
Hospital Stay
for
Hysterectomy
27.14 10.85 54.27 214.24 50.41 302.45 26.49 19.87 33.11 155.96 77.98 233.94 171.87 108.03 294.64
Hospital Stay
for Other
Surgery
32.56 10.85 54.27 214.24 50.41 302.45 90.88 19.87 132.45 155.96 77.98 233.94 82.50 82.50 82.50
Use of
Anesthesia
143.82 143.82 143.82 10.08 10.08 10.08 N/A 0.00 0.00 20.58 17.96 23.20 N/A 0.00 0.00
Blood
transfusion
(cost per pint)
9.95 12.48 12.48 11.76 0.50 20.16 N/A 0.00 0.00 47.84 30.14 65.53 19.48 11.79 29.46
Note: N/A indicates service or resource not available or item is bundled with reimbursement for delivery-based care
Note: Antibiotic prices for Guatemala estimated from external source, other surgery has same cost as hysterectomy
For Kenya, other surgery costs assumed same as for hysterectomy
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to the overall sample. Those having cesarean section de-
liveries were the same mothers for both the overall sam-
ple and sub-sample. Guatemala had the highest rates of
cesarean section deliveries (28% in the overall sample
and 34% in high-risk pregnancies). Other countries
ranged from 1 to 11% cesarean section rates in the over-
all sample, and 3 to 15% for the higher-risk, more com-
plicated pregnancy group.
Maternal and neonatal complications resulting in
additional healthcare use
Table 5 presents data from a sub-sample collected in
each country during the CRCT, showing when complica-
tions occurred during pregnancy and what types of ser-
vices and locations were reported for healthcare services
for mothers. The majority of pregnancy-related compli-
cations in the sub-sample occurred at the time of
Table 3 Event probabilities for delivery settings and maternal and neonatal events related to complications
DRC Kenya Zambia Guatemala Pakistan
Location of child delivery and probability of Cesarean section delivery
Delivery location and probability (N for overall sample)a 4818 9170 9367 16,287 7243
Overall sample average
Local village or home setting (%) 19.51 26.52 18.04 42.11 37.48
Non-hospital clinic setting (%) 66.15 54.61 58.13 0.86 29.30
Hospital setting (%) 14.34 18.87 23.83 57.03 33.22
Proportion of deliveries with Cesarean section delivery (all trial participants) (%) 1.12 2.26 1.20 27.78 11.46
Higher-risk (complicated pregnancy) sub-sample of overall sample (n) 953 1143 1759 5458 2367
Estimated proportion of higher-risk pregnancies (% of total sample per country) 19.78 12.46 18.77 33.51 33.00
Delivery location and probability
Local village or home setting (%) 18.47 21.00 14.10 37.71 35.02
Non-hospital clinic setting (%) 62.33 52.06 52.25 0.64 25.64
Hospital setting (%) 19.20 26.95 33.66 61.65 39.33
Type of delivery
Proportion of deliveries with Cesarean section delivery (%) 3.67 7.87 3.47 34.15 14.91
Maternal health-related complication probabilitiesa
Maternal healthcare resource use (N) 145 142 163 1282 147
Antibiotics (% yes) 86.25 78.70 43.95 83.30 93.90
Hysterectomy after complication (% yes) 2.85 0.65 0.00 0.90 0.00
Other surgery (% yes) 2.85 2.75 0.45 11.30 2.05
Anesthesia (% yes) 17.50 30.35 8.40 61.35 2.75
Blood transfusion (% yes) 13.25 6.10 3.20 4.50 21.70
Inpatient ultrasound (% yes) 9.50 11.65 8.20 78.20 27.90
Chest radiograph (% yes) 2.00 0.00 0.95 1.80 1.40
Neonatal health-related complication probabilitiesb
Select neonatal healthcare resource use (sample ranges in countries per use type,
N)c
4660-
4908
7493-
9288
6363-
9456
15,827-16,
394
3544-
7284
Neonatal hospitalization (% yes) 0.15 0.75 0.50 3.35 2.40
Neonatal bath within six hours after delivery (% yes) 0.10 27.85 0.80 36.80 13.30
Neonatal antibiotics (% yes) 1.55 0.50 0.20 3.80 10.80
Neonatal oxygen use (% yes) 0.00 0.80 0.35 4.30 12.05
Mechanical ventilation (% yes) 0.40 0.45 0.15 0.55 0.20
Medical eye care (% yes) 1.25 15.20 1.00 56.25 0.90
Medicinal cord care (% yes) 2.65 2.00 1.40 99.30 2.30
Vitamin K (% Yes) 0.10 1.15 0.45 56.85 3.40
aMaternal health-related complications reported from sub-sample direct data collection from clinical trial
bNeonatal health-related complications reported from Maternal Health Registry
cSample size range for specific neonatal complications included some variability
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Table 4 Simplified country-level use and cost estimates of antenatal care services and delivery by setting
DRC Kenya Zambia Guatemala Pakistan
Antenatal care (ANC) visits (N for overall sample) 4819 9177 9369 16,288 7251
Weighted-mean number of ANC visits overall, per person (#) 3.25 3.60 3.20 4.45 3.90
Mean per person cost for average number of ANC visits with no ultrasound (using mean # of
ANC visits for overall sample) (2015 USD)
15.28 15.87 18.37 14.58 14.53
Overall number of visits (exams) with ultrasound (sub-sample of patients receiving at least one
ultrasound) (n)
2291 3380 4408 7935 2404
Estimated percent of per person ultrasound visits (% for each)
1 24.31 50.36 40.86 17.10 35.19
2 65.26 46.54 55.51 69.32 61.06
3 9.56 2.84 3.43 12.70 3.45
> = 4c 0.87 0.27 0.20 0.88 0.29
Weighted mean for number of ultrasound visits (of those having > = 1) (#) 1.87 1.53 1.63 1.97 1.69
Weighted-mean cost estimate for weighted-mean number of ANC visits with ultrasound (as-
sumed outpatient) (2015 USD)
24.00 15.81 21.59 8.28 7.25
Calculated weighted-mean cost of overall ANC visits (average number of overall ANC visits net
of estimated ANC visits with ultrasound to avoid double counting) (2015 USD)
30.48 24.93 30.60 16.40 15.49
Delivery location and probability (N for overall sample)a 4818 9170 9367 16,287 7243
Overall sample average (% for each)
Local village or home setting (%) 19.51 26.52 18.04 42.11 37.48
Non-hospital clinic setting (%) 66.15 54.61 58.13 0.86 29.30
Hospital setting (%)
Hospital delivery with cesarean section (%) 1.12 2.26 1.20 27.78 11.46
Hospital delivery without cesarean section (%) 13.22 16.61 22.63 29.26 21.76
Cost of delivery by typed (2015 USD)
Average per person cost of deliveries with cesarean section delivery (2015 USD) 108.50 156.27 99.34 44.46 202.85
Average per person cost, non-cesarean deliveries (2015 USD) 41.68 55.20 90.32 26.02 75.88
Calculated weighted-mean cost per mother estimate for deliveries for overall sample (non-
Cesarean and Cesarean-Section; includes non-high-risk pregnancies and high-risk pregnancies)b
(2015 USD)
22.54 31.43 51.96 22.81 57.98
Higher-risk (complicated pregnancy) sub-sample of overall sample (n) 953 1143 1759 5458 2367
Estimated proportion of higher-risk pregnancies (% of total sample per country) 19.78 12.46 18.77 33.51 33.00
Delivery location and probability
Local village or home setting (%) 18.47 21.00 14.10 37.71 35.02
Non-hospital clinic setting (%) 62.33 52.06 52.25 0.64 25.64
Hospital setting (%)
Hospital delivery with cesarean section (%) 3.67 7.87 3.47 34.15 14.91
Hospital delivery without cesarean section (%) 15.53 19.07 30.19 27.50 24.42
Cost of delivery by typed (2015 USD)
Average per person cost of deliveries with cesarean section delivery (2015 USD) 108.50 156.27 99.34 44.46 202.85
Average per person cost, non-cesarean deliveries (2015 USD) 41.68 55.20 90.32 26.02 75.88
Calculated weighted-mean per mother cost estimate for deliveries for high-risk (complicated)
pregnancies (non-Cesarean and Cesarean-Section procedures)b (2015 USD)
25.37 40.10 57.49 24.88 65.15
aDelivery location included a small number of missing observations from overall sample
bNon-hospital delivery costs based on facility estimate and proportion of non-cesarean section facility estimate (assumed village-level = 25% of hospital, non-
hospital clinic = 50% of facility cost estimate)
All cesarean section deliveries were assumed to be conducted in hospital facility
cPersons with > 4 ANC visits with ultrasound assumed to have four ultrasound visits for cost calculation
Higher-risk pregnancies included multiple gestation, placenta previa, and breech presentation
dCost estimates for delivery type for with and without cesarean section delivery from Table 2 (all costs 2015 USD)
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Table 5 Sub-sample probabilities and cost estimates (2015 USD) for complication-related healthcare use
DRC Kenya Zambia Guatemala Pakistan
Use of hospital / referral services for treatment of complicationsa
When did the complication occur, sub-sample of overall sample (N) 172 173 182 1351 192
During antenatal care (%) 42.10 22.00 31.90 27.00 2.70
At time of delivery (%) 49.6 69.90 65.70 68.50 95.40
Post delivery (%) 8.40 8.10 2.50 4.50 2.00
Was mother referred for a treatment of a serious pregnancy complication, (N) 172 173 182 1351 192
Yes (%) 92.70 79.15 89.15 96.95 77.10
No (%) 7.30 20.85 10.85 3.05 22.90
Did mother go to the referral facility, (N) 150 137 163 1309 147
Yes (%) 88.50 97.75 98.65 97.50 100.00
No (%) 11.50 2.25 1.35 2.50 0.00
What type of provider did mother see during visit (checked all that applied), (N) 141 134 160 1276 147
OBGYN (%) 0.60 22.55 50.10 24.55 36.70
Medical Officer (%) 37.55 27.20 29.60 76.05 29.30
Clinical Officer/Medical Assistant (%) 3.95 21.80 2.35 0.95 0.70
Nurse (%) 76.05 61.95 81.45 92.80 13.60
Sonographer (%) 7.40 7.05 5.10 0.10 0.70
Other (%) 2.10 0.00 0.00 0.25 19.75
Where was referral care received (checked all that applied), (N) 141 134 160 1276 147
Hospital Wards (%) 0.60 12.45 0.45 10.85 15.65
Intensive Care Unit (%) 0.00 0.85 0.00 0.80 0.00
Casualty (%) 0.85 0.00 0.00 88.55 0.00
Outpatient Facility (%) 0.00 11.85 0.95 1.05 1.40
Maternity Ward (%) 65.10 73.50 98.60 6.20 43.50
Other (%) 33.45 1.35 0.00 0.75 40.80
Was mother admitted, N (%) 141 134 160 1276 147
Yes 87.30 85.10 91.95 100.00 89.10
No 12.70 14.90 8.05 0.00 10.90
Select maternal healthcare resource use (sub-sample collected in countries)b
Maternal healthcare resource use (N) 145 142 163 1282 147
Antibiotics (% yes) 86.25 78.70 43.95 83.30 93.90
Estimated cost per antibiotic treatment (2015 USD) 7.00 36.97 3.31 12.00 9.58
Hysterectomy after complication (% yes) 2.85 0.65 0.00 0.90 0.00
Estimated cost per hysterectomy treatment (2015 USD) 27.14 214.24 26.49 155.96 171.87
Estimates cost hospital stay for hysterectomy (2015 USD) 27.14 214.24 26.49 155.96 171.87
Other surgery (% yes) 2.85 2.75% 0.45 11.30 2.05
Estimated cost per non-hysterectomy surgery (2015 USD) 32.56 214.24 90.88 155.96 82.50
Estimates cost hospital stay for other surgery (2015 USD) 32.56 214.24 90.88 155.96 82.50
Anesthesia (% yes) 17.50 30.35 8.40 61.35 2.75
Estimated cost per use of anesthesia (if available) (2015 USD) 143.82 10.08 0.00 20.58 0.00
Blood transfusion (% yes) 13.25 6.10 3.20 4.50 21.70
Estimated cost per blood transfusion (if available) (2015 USD) 9.95 11.76 0.00 47.84 19.48
Inpatient ultrasound (% yes) 9.50 11.65 8.20 78.20 27.90
Estimated cost per inpatient ultrasound (2015 USD) 16.28 10.64 13.25 5.50 4.30
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delivery or post-delivery, accounting for roughly 50–70%
of complications, with a greater portion occurring at de-
livery in Pakistan (95%). Table 5 also presents data from
two sub-samples to estimate costs associated with ma-
ternal complication and neonatal complication events.
Based on the probability and cost estimates reported, an
additional 4─75 USD is estimated to be expended by a
health facility to manage select maternal and neonatal
complications in a cohort similar to our CRCT and GN
MNHR. Cost estimates in Zambia were particularly low
relative to per capita income level, due to some cost pa-
rameters not being available (zero-dollar estimates) or
included as part of bundled, episode-based delivery-
related reimbursement amounts. Another factor influen-
cing complication-related costs across countries was
variable frequencies reported of certain complications in
our sub-samples. Limited testing of ranges of costs for
resources in Zambia with a zero USD estimate does not
greatly increase overall costs in Zambia or in other
countries, due to the overall low frequency of these
events. Complication management cost estimates were
highest on average in Guatemala, influenced by a higher
frequency of reported neonatal events (Table 5) com-
pared to other countries, and that most item-level cost
estimates were non-zero.
Figure 1 presents sensitivity testing of cost estimates in
Table 4 for ANC costs and delivery costs. Some coun-
tries had tighter ranges of low and high unit cost esti-
mates for ANC visits, e.g., Guatemala and Pakistan, and
thus had smaller changes in these base-case costs due to
Table 5 Sub-sample probabilities and cost estimates (2015 USD) for complication-related healthcare use (Continued)
DRC Kenya Zambia Guatemala Pakistan
Chest radiograph (% yes) 2.00 0.0 0.95 1.80 1.40
Estimated cost per chest radiograph (2015 USD) 13.76 8.07 5.30 9.70 2.50
Estimated mean facility-level per person added cost estimate for maternal complication
events (2015 USD), for typical cohort of patients
37.75 48.68 3.41 67.31 17.83
Select neonatal healthcare resource use (sample ranges in countries per use type, N)c 4660-
4908
7493-
9288
6363-
9456
15,827-16,
394
3544-
7284
Neonatal hospitalization (% yes) 0.15 0.75 0.50 3.35 2.40
Estimated per person cost for neonatal hospitalization (2015 USD) 5.44 2.90 46.30 77.61 73.31
Neonatal bath within six hours after delivery (% yes) 0.10 27.85 0.80 36.80 13.30
Estimated per person cost for neonatal bath (2015 USD) 0.00 0.00 1.32 1.31 0.00
Neonatal antibiotics (% yes) 1.55 0.50 0.20 3.80 10.80
Estimated per person cost for antibiotics (2015 USD) 7.00 36.97 3.31 12.00 9.58
Neonatal oxygen use (% yes) 0.00 0.80 0.35 4.30 12.05
Estimated per person cost of oxygen (2015 USD) 29.31 1.01 1.85 6.16 4.66
Mechanical ventilation (% yes) 0.40 0.45 0.15 0.55 0.20
Estimated per person cost for ventilation (2015 USD) 0.00 0.00 1.32 39.58 4.66
Medical eye care (% yes) 1.25 15.20 1.00 56.25 0.90
Estimated per person cost for eye care (2015 USD) 0.71 0.20 1.32 4.72 0.00
Medicinal cord care (% yes) 2.65 2.00 1.40 99.30 2.30
Estimated per person cost for cord care (2015 USD) 0.00 0.00 1.21 0.66 0.00
Vitamin K (% Yes) 0.10 1.15 0.45 56.85 3.40
Estimated cost per vitamin K treatment (2015 USD) 1.90 2.02 0.74 1.31 0.58
Estimated mean facility-level per person added cost estimate for neonatal complication
events (2015 USD), for typical cohort of patients
0.13 0.27 0.22 8.15 0.03
Combined estimated mean facility-level per person added cost estimate for maternal and
neonatal complication-related events (2015 USD), for typical cohort of patients
37.88 48.94 3.63 75.46 17.87
aPercentages for use of hospital services due to complications during pregnancy and percent of complications reported are based on non-weighted average
reported in cohort sub-samples in countries
bProbability and cost estimates presented in the lower portion of Table 5 are taken from Table 2 (unit costs) and Table 3 (complication probabilities), and are not
based on the event probabilities in the upper portion of Table 5
Samples were from different data sources for probabilities for maternal health major procedures/treatments, and neonatal events
If item-level or event-level facility cost estimate $0, NA, or missing from Table 3, $0 estimate used for calculation in Table 5
cExact sample size of neonatal healthcare use varied slightly per event (range is presented per country)
Components of combined estimates for maternal and neonatal costs may not reflect rounding precision given USD two decimal standard
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adjusting parameter values. Other countries, e.g., DRC,
exhibited more variability in ANC visit cost ranges and
thus estimated average cost ranges were greater in sensi-
tivity testing. Low- and high-range estimates in DRC
were particularly large for visits with antenatal screening
US. For example, combined visits with and without ante-
natal screening US in DRC ranged from 4─79 USD, due
to a greater estimated range in US costs (high of 30
USD per visit). Delivery cost estimates in DRC, on the
other hand, were lower than in other countries, but close
to Guatemalan delivery cost estimates. Delivery costs in
Pakistan demonstrated a higher level of variability with-
out and with inclusion of a prolonged hospital stay asso-
ciated with cesarean section deliveries (37─92 USD and
51─126 USD, respectively) compared with a base-case
average of 58 USD and 82 USD, respectively (Fig. 1).
These estimates were influenced by average cesarean
and non-cesarean delivery-based unit costs being rela-
tively high in Pakistan compared to other countries, as
well as the second highest cesarean section rates among
countries. Higher delivery costs in Guatemala were influ-
enced by having the highest rates of cesarean sections,
not higher average unit cost estimates for deliveries. In
all countries, adjusting the proportional cost for local/
village and clinic-level deliveries relative to hospital facil-
ity delivery costs had less influence on average base-case
estimates compared to using the low- and high-end of
the delivery-related unit cost estimates. Due to lower
rates of cesarean section deliveries in the three African
countries compared to Guatemala and Pakistan, includ-
ing additional hospital stays associated with cesarean de-
liveries had minimal impact on overall delivery cost
estimates.
Discussion
We estimated average costs for ANC-related service
use and delivery-related services, as well as for select
complication events in five LMICs in different global
regions: DRC, Kenya, Zambia, Guatemala, and
Pakistan. Our economic study was part of a large
CRCT and ongoing maternal health registry to sup-
port efforts to better document resource use and
costs associated with antenatal screening US and
other healthcare services [8]. We estimated a broad
range of ANC-related resource use from participating
countries in order to inform global health researchers
and health policy-making stakeholders, as well as to
Fig. 1 Two-way and one-way sensitivity of ANC visits and deliveries
(2015 USD). Note: scale of cost range adapted for some higher-cost
estimates for Guatemala and Pakistan Estimates of ANC visit costs
with and without ultrasound used base-case estimates and cost
ranges of each type of ANC visit (with and without ultrasound)
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be available as inputs in subsequent economic assess-
ments related to these LMICs.
Our initial goal was to determine if routine ante-
natal screening US was economically efficient due to
lower costs overall to provide screening, even if other
outcomes were similar. For this type of economic
study, we would often use a “societal perspective” that
looks at all direct medical and indirect costs in “op-
portunity cost” terms from multiple perspectives, and
compare costs with effectiveness outcomes. However,
in terms of the CRCT’s clinical effectiveness evidence
for the five countries combined, and in individual
countries, the primary composite endpoint of mater-
nal mortality, near-miss maternal mortality, stillbirth,
and neonatal mortality did not differ significantly be-
tween the US intervention arm (n = 24,008 pregnant
women) and the control arm (n = 22,896 pregnant
women). Process-related outcomes, such as the mean
number of ANC visits, delivery location, cesarean sec-
tion delivery rates, complicated deliveries, or six-week
post-partum hemorrhage events, were also not statis-
tically different between CRCT arms [12]. Since
effectiveness in all countries was so similar, cost-
effectiveness assessment was not a practical approach
to compare groups. Therefore, we estimated unit
costs for particular ANC and delivery-related resource
use, and constructed key event average cost estimates
from these unit costs within each country, based on
events from the CRCT and GN MNHR [12, 13]. We
report cost assessments for combined treatment
groups in countries based on estimates of average
costs of ANC visits (with and without antenatal
screening US), delivery events, and the management
of select complications.
In this economic study conducted alongside the
CRCT, we were able to successfully estimate average
costs associated with resources required for most ANC
procedures and services in participating countries, using
a facility perspective. Estimates were primarily based on
reimbursement schedules and expected payment
amounts when available. Our local country experts ob-
tained hospital or facility administration assistance when
“prices” were not readily available publicly. Overall, the
antenatal screening US group was essentially dominated
by standard of care, with higher ANC visit costs and
similar effectiveness outcomes. There is more time and
higher expected average unit costs associated with ante-
natal screening US visits compared to non-US ANC
visits. We did not observe differences in the frequency of
hospital deliveries or cesarean section deliveries between
CRCT groups in countries, as we initially expected.
Antenatal screening US was expected to increase hos-
pital costs, through improving the planning of deliveries
for higher-risk pregnancies. Hospital events and thus
expected average hospital costs were not different be-
tween randomized groups. However, for US, there would
be additional costs associated with acquiring US equip-
ment, training sonographers, and maintaining portable
US equipment. Estimating these costs was beyond our
study’s scope.
To put our findings in context, it helps to recognize a
few key country-level characteristics that influence the in-
terpretation of findings and suggest further research is
needed in these countries representing different global re-
gions. The five LMICs in the CRCT are diverse in terms
of gross domestic product per capita, health spending per
capita, maternal and neonatal mortality rates, and use of
US overall. Countries had differences in basic infrastruc-
ture, health system access or readiness, and insurance
coverage policies. Our primary focus was on public facil-
ities serving the largest portions of populations in partici-
pating countries. Despite select differences in cost
estimates for resource use among countries, absolute and
relative costs associated with antenatal care services were
generally aligned with per capita income levels.
Each country included publicly provided healthcare
services, although Pakistan and Guatemala also have a
greater prevalence of private health sector facilities and
services, including the provision of US services. Al-
though we did not have a formal evaluation of the qual-
ity of private sector-provided US services, used by some
in the control groups, our clinical team was able to ver-
ify the quality of sonographer training and the antenatal
screening US exams performed in the intervention clus-
ters, to ensure sonographers were meeting training re-
quirements and that US exams met appropriate clinical
standards. More advanced equipment, services, or spe-
cialty healthcare personnel were not available in some
countries or in some facilities, making precise estimation
challenging. Therefore, our unit cost estimates some-
times had large low-to-high ranges. We used a country-
level average for all facilities within countries, if a
particular service was available at least one facility. Our
ANC use and delivery-related cost estimates provide ex-
tensive unit cost data and event-related cost estimates
for the five participating countries. We also tested sensi-
tivity ranges related to average costs for ANC visits and
delivery events using different unit cost scenarios.
We acknowledge the importance of having appropri-
ately trained sonographers for our screening study. In
terms of training the sonographers in the CRCT who
conducted the antenatal screening ultrasound exams, we
developed an extensive training curriculum that is pub-
lished elsewhere [10, 20–23]. There is a severe shortage
of trained sonographers serving rural communities in
LMICs, including the five countries that participated in
the CRCT. It would not have been possible to recruit
fully trained sonographers to staff all of the 25
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intervention clusters in the study. A secondary objective
of the study was to evaluate whether US naïve healthcare
workers (midwives, clinical officers, nurses, radiogra-
phers) could be trained in a short, intensive course
followed by a period of supervised scanning to provide
accurate screening ultrasound. The concept was not to
train independent sonographers but rather to train ex-
tenders of the fully trained sonographers located at des-
ignated referral facilities. Any patient with a suspected
abnormality identified at an intervention cluster health
center would be referred to the referral hospital for con-
firmation by a fully trained sonographer.
There were similarities in health system structures in
some countries, such as Kenya and Zambia, and numer-
ous differences in others, such as with the DRC,
Pakistan, and Guatemala. Since most participating hospi-
tals in the CRCT were rural, resource availability was
more limited in these facilities compared to urban hospi-
tals or teaching hospitals in countries. Particularly in
rural areas, the lack of public transportation infrastruc-
ture and long travel distances contribute to challenges in
patients accessing health clinics and hospitals. The
Kenyan and Zambian health systems largely consist of
public facilities providing services, as well as basic public
healthcare insurance coverage and government pay-
ments to facilities for delivery services, with some private
centers and private insurance options used mostly by
employees of larger companies. In contrast, in the DRC
there is essentially no public health insurance coverage
and patients typically pay “out-of-pocket” or make other
arrangements with a health center to receive services.
Guatemala and Pakistan have a mixture of public and
private sector healthcare provision, with urban areas
having more private clinics, partly related to higher-
income levels and market structures. In addition, several
countries rely on external financial donors and non-
governmental organizations (NGOs) to subsidize
healthcare and/or infrastructure spending, influencing
short-term use and cost scenarios as well as creating de-
pendence or constraints on longer-term sustainability.
The DRC, the country with the lowest per capita income
level, had a synchronous complicating factor independent
of the trial. Hospital care was subsidized by an inter-
national non-governmental organization, lowering the fi-
nancial burden on families. However, the longer-term
sustainability of these types of initiatives are uncertain and
may reduce the use of hospital services in the absence of
such subsidies. Hospital and clinic resources in the DRC
are limited [24–26] and our individual cost estimates may
represent higher costs than feasible for families to afford
without subsidization. As our sensitivity analysis showed,
base-case cost estimates in the DRC varied widely based
on unit cost estimates for visits and deliveries. As ex-
pected, DRC had fewer hospital deliveries and cesarean
section deliveries compared to other countries, with low
rates similar to Kenya and Zambia. Since most deliveries
in these three countries occurred in non-hospital clinic
settings or in the home/village, lowering the assumed cost
of village-level or clinic-level deliveries, as a proportion of
hospital delivery costs, had the effect of lowering expected
overall average delivery costs.
Since US equipment can be used to assess many pa-
tients during its life cycle, the average per patient or per
event usage cost is expected to be relatively low when al-
located among thousands of patients during each of
multiple years. However, investment and maintenance
costs, for equipment and sonographer training, and for
subsequently higher sonographer wages, may be prohibi-
tive in LMICs. Including stakeholder (e.g., health facility)
investments in ultrasound equipment would add costs to
our estimates of care-related costs presented in the
current paper. Although antenatal screening US does
not appear to result in more efficient or lower cost out-
comes, we are not able to claim that portable US is not
efficient overall or for specific indications in a clinic or
hospital setting. Some studies have shown a potential
clinical utility of US in assessing gynecologic, abdominal,
musculoskeletal, cardiovascular, pulmonary, traumatic,
and other conditions [27]. Estimating secondary effects
of having portable US available in clinics and hospitals
was outside the scope of our assessment. For ultrasound
equipment purchases, facilities and other stakeholders
would have to estimate benefits and costs of their overall
investment, including estimating expected return on in-
vestment considering all potential uses of ultrasound.
Participating clusters at each country site had desig-
nated referral hospitals where antenatal screening ultra-
sound findings identified at the rural health centers were
confirmed by fully-trained sonographers. The details of
each country site referral process varied somewhat, but
when a referral was required from a remote health cen-
ter, the hospital sonographer was texted with the patient
name and provisional diagnosis. The patient was given a
report from the health center along with key antenatal
screening ultrasound images to be given to the hospital
sonographer. The importance of attending the referral
was explained to the patient. Not surprisingly, the suc-
cess of the referral process varied somewhat from health
center to health center and from country to country.
Follow-up and referral indications were consistently per-
formed by a “referral algorithm” at each health center.
Our resource use and cost identification study in-
cluded several limitations influencing data collection and
interpretation. Despite efforts to maintain consistency in
data collection among countries, we collected cost infor-
mation from a variety of sources to estimate average
antenatal care and delivery-related costs. We did not
specifically estimate the cost of patient referrals for
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elevated care during the study. The proportion of pa-
tients receiving referrals were not statistically different
between the randomized groups in any country. We did
not assess all health centers within countries, and sur-
veyed a sampling of representative centers. Different
countries had varying amounts of available data for ser-
vices and prices, e.g., reimbursement schedules. We esti-
mated outpatient and inpatient service costs for
variables of interest, although specific services or equip-
ment were not available in some countries and/or in
some facilities, or were part of bundled reimbursement
for deliveries. Thus, we could not estimate unit costs for
all items but we did not impute values for missing cost
estimates. We estimated costs based on the average
number of ANC visits, delivery locations, complication-
related use reported in the CRCT or GN MNHR, rather
than using retrospective claims data or tracking hospital-
izations for patients to assess use. With more than 45,
000 deliveries and approximately 160,000 antenatal visits
during the CRCT, the cost of collecting resource use on
each of these was prohibitively expensive. We acknow-
ledge that reimbursement amounts may not represent
the cost of service provision but only serve as proxies for
costs, particularly for multi-use equipment and multi-
function personnel. We also did not assess indirect costs,
such as time costs or productivity costs. Routine ante-
natal screening ultrasound is likely to add to patient-
level costs, without expected effectiveness gains.
Conclusion
Despite substantial differences among countries in infra-
structures and health system capacity, there were similar-
ities in resource allocation, delivery location, and country-
level challenges for providing high-quality ANC. Overall,
there was no clear suggestion that adding antenatal
screening US would result in either major cost savings or
major cost increases. However, antenatal screening US
would have higher training and maintenance costs. Given
the lack of clinical effectiveness evidence and greater re-
source constraints of LMICs, it is unlikely that introducing
antenatal screening US would be economically efficient in
these settings—-on the demand side (i.e., patients) or sup-
ply side (i.e., healthcare providers).
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